Why the study?
Does low-dose aspirin prevent cardiovascular disease in women for primary prevention?
Does low-dose aspirin prevent cardiovascular disease in women for primary prevention?
Low-dose aspirin for primary prevention in women should be restricted to specific high-risk groups aged 40 to 70 years due to the competing risk of bleeding.
Advises selective aspirin consideration in higher-risk midlife women; leaves open need for sex-specific RCTs to confirm thresholds.
For primary prevention, low-dose aspirin should be considered in women aged 40 to 70 years with a 10-year cardiovascular risk of 20% or more or in women with diabetes and a 10-year cardiovascular risk of 10% or more. The risk of bleeding outweighs the benefits in low-risk women and in women aged 70 years and older.
No takes yet. Share an insight, caveat, or question.
Shufelt et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: